[Trending] Global Effervescent Tablet Market Size & Share to Hit $ 8.7 Billion by 2030, Driven by a Strong CAGR of 6.5%: The growing incidence of chronic disease to boost the market growth - Zion Market Research
June 27, 2023 06:22 ET
|
Zion Market Research
NEW YORK, United States, June 27, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Effervescent Tablet Market Comprehensive Analysis, Historical Data, and...
Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105
June 05, 2023 08:00 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
New Research Reveals the Prevalence of Drug-Drug Interactions and the Economic Impact on the Healthcare System
November 05, 2018 14:00 ET
|
Aegis Sciences Corporation
Studies show an alarming prevalence of concurrent ingestion of interacting substances by patients and that providing physicians with clear, objective information leads to a reduction of interactions...
Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition
March 14, 2018 07:45 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 14, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company today announced that an abstract related to the Phase 3 SECURE study for...
Agile Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
August 22, 2017 07:30 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that Al Altomari, Chairman and CEO will...
Agile Therapeutics Announces Proposed Offering of Common Stock
August 02, 2017 16:05 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that it intends to offer and sell shares of...
Agile Therapeutics Reports Second Quarter 2017 Financial Results
July 28, 2017 07:30 ET
|
Agile Therapeutics, Inc.
Cash Expected to Fund Operations into Q2 2018 FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of December 26, 2017 PRINCETON, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Agile...
Agile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla® at ACOG 2017
May 06, 2017 14:05 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 06, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women’s healthcare company, today announced the presentation of additional results of its Phase 3 SECURE...
Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Women’s Health
April 27, 2017 07:30 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company announced today that a presentation entitled “An Update on Hormonal...
Agile Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare Conference
February 14, 2017 16:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that its Chief Executive Officer, Al...